The aim of the study is to assess the ability of Levosimendan to reduce the postoperative acute kidney injury in pediatric patients undergoing surgery for congenital heart disease (CHDs). Young children, between the age of 1 to 12 months, with congenital heart disease in need of elective heart surgery will be included in this study.